Skip to main content

Table 1 Clinical and biochemical characteristics of 20 patients with type 2 diabetes at baseline and after 4 months of nateglinide or rosiglitazone therapy

From: Effects of nateglinide and rosiglitazone on pancreatic alpha- and beta-cells, GLP-1 secretion and inflammatory markers in patients with type 2 diabetes: randomized crossover clinical study

Variables Baseline Nateglinide p Baseline Rosiglitazone p
After 4 months After 4 months
Median (25th–75th) Median (25th–75th) Median (25th–75th) Median (25th–75th)
Body weight (kg) 67.9 (64.1–81.0) 70.0 (64.5–78.0) 0.073 69.0 (63.9–77.0) 68.9 63.6–77.9 0.984
Hba1c (%) 7.45 (7.0–8.3) 6.65 (5.7–7.8) 0.032 7.2 (6.8–8.1) 6.6 5.5–7.5 0.036
Homa Beta 40.7 (28.8–52.0) 51.3 (28.7–73.0) 0.126 33.6 (26.8–59.0) 51.6 30.9–69.9 0.005
Total-c (mg/dL) 223.5 (178.5–235.3) 194.0 (182.0–213.0) 0.036 213.0 (184.0–230.0) 211.0 201.0–245.0 0.277
HDL-c (mg/dL) 44.5 (37.8–57–8) 44.5 (34.0–55.0) 0.360 45.0 (40.0–56.0) 48.0 38.0–55.0 0.347
LDL-c (mg/dL) 144.0 (111.0–153.5) 131.5 (109.5–142.0) 0.145 152.0 (106.0–157.0) 142.0 124.0–168.0 0.355
CRP (mg/L) 5.2 (1.87–8.91) 3.79 (1.63–7.64) 0.052 4.16 (2.23–8.37) 3.10 (0.87–6.34) 0.042
TGF β (pg/mL) 44.1 (34.2–51.1) 45.3 (32.2–49.4) 0.247 42.7 (37.8–47.9) 38.3 32.0–45.8 0.001
Interleukin-6 (pg/mL) 2.54 (1.45–5.66) 2.37 (1.16–3.53) 0.108 2.71 (1.46–4.17) 2.00 1.42–3.89 0.520
leptina (ng/mL) 14.9 (7.6–21.0) 17.9 (10.0–20.8) 0.808 13.1 (6.0–19.3) 16.2 7.0–24.1 0.199
sICAM-1 (ng/mL) 233.8 (179.7–261.5) 214.9 (186.7–263.3) 0.391 223.6 (171.3–241.6) 218.0 173.8–246.0 0.573
TNF α (pg/mL) 1.71 (1.18–2.50) 1.52 (1.08–2.91) 0.235 1.49 (1.23–2.09) 1.43 1.18–2.18 0.760
fibrinogen (mg/dL) 316.0 (276.8–375.0) 336.5 (297.8–357–5) 0.433 337.0 (296–397) 322.0 (262.5–363.8) 0.024
PA-1 activity (UI/mL) 27.7 (14.4–43.8) 24.7 (14.7–40.3) 0.55 15.9 (11.6–40.0) 12.7 8.0–19.0 0.040
platelet aggregation 90.3 (80.1–96.0) 90.0 (81.0–92.6) 0.601 89.0 (76.4–94.5) 90.9 76.0–95.0 0.643
  1. Wilcoxon matched pairs tests were performed to compare the differences before and after the 4 months of therapy for each group
  2. Italic values indicate statistical significance at p < 0.05
  3. CRP reactive protein, HDL-c HDL cholesterol, LDL-c LDL-cholesterol, PAI-1 plasminogen activator inhibitor, sICAM-1 intercellular adhesion molecule-1, TGFβ transforming growth factor beta, TNFα tumor necrosis factor alfa, Total-c total cholesterol
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us